Earl L Goehring

Years Active: 2018-2024
Publications (10 Years): 5

Bausch Health (United States)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bausch Health (United States) Mar 11 2019

United States

Director :: Global Pharmacovigilance & Risk Management

PharmaLex US Corporation Apr 01 2018 - Dec 18 2018

United States

Director Research :: Pharmacovigilance, Epidemiology & Risk Management

Degge Group (United States) Jan 19 1999 - Mar 31 2018

United States

Managing Director :: Research

Publications

Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Sigal Kaplan, Earl L Goehring, Sigal Melamed-Gal, Bao-Anh Nguyen-Khoa, Helena Knebel, Judith K Jones
Modafinil and the risk of cardiovascular events: Findings from three US claims databases. Pharmacoepidemiology and drug safety 27 (11) (2018)

Earl L Goehring.css-eqlu8i{font-size:small;padding-left:4px;}